TipRanksTop Financial ExpertsInsidersBain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences Investors, LLC Insider Profile

4 Followers
Bain Capital Life Sciences Investors, LLC, Ten Percent Owner at Dicerna Pharma, holds 3.16M shares in Kyverna Therapeutics, Inc. (Ticker: KYTX), holds 4.03M shares in Solid Biosciences (Ticker: SLDB), holds 5.70M shares in Annexon Biosciences (Ticker: ANNX).
tipranks
Bain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences Investors, LLC
Dicerna Pharma (DRNA)
Ten Percent Owner

Ranked #9,076 out of 97,372 Corporate Insiders

Profitable Transactions

63%
10 out of 16 Profitable Transactions

Average Return

+12.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$509M
46.17%
17.46%
8.14%
7.71%
20.53% Others
A breakdown of Bain Capital Life Sciences Investors, LLC's holdings

Insider Roles

Springworks Therapeutics
(SWTX)
Ten Percent Owner
Kyverna Therapeutics, Inc.
(KYTX)
Ten Percent Owner
Arcutis Biotherapeutics
(ARQT)
Ten Percent Owner
Marinus
(MRNS)
Ten Percent Owner
+5 other positions
Roles that Bain Capital Life Sciences Investors, LLC holds in companies

Most Profitable Insider Trade

Stock:
Springworks Therapeutics
(SWTX)
Rating:Informative Buy
Date:Sep 19, 2019 - Sep 19, 2020
Return:+96.70%
The most profitable trade made by Bain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences Investors, LLC's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
DRNA
Dicerna Pharma
Nov 21, 2019
Informative Sell
38.55M
$213.28M
Marinus
Dec 19, 2017
Ten Percent Owner
Informative Sell
10.02M
$39.22M
Replimune Group
Jul 26, 2018
Ten Percent Owner
Informative Buy
7.50M
$24.73M
Springworks Therapeutics
Aug 12, 2021
Ten Percent Owner
Informative Sell
70.25M
$234.90M
Arcutis Biotherapeutics
Feb 06, 2020
Ten Percent Owner
Uninformative Buy
$41.42M
Annexon Biosciences
May 30, 2023
Ten Percent Owner
Informative Buy
639.00K
$31.30M
APTX
Aptinyx
Oct 27, 2020
Informative Buy
10.00M
$853.61K
Rapid Micro Biosystems
Jul 21, 2021
Ten Percent Owner
Uninformative Buy
$8.43M
Xilio Therapeutics
Dec 10, 2021
Ten Percent Owner
Informative Buy
410.07K
$1.85M
Solid Biosciences
Jan 12, 2024
Director, Ten Percent Owner
Uninformative Buy
5.00M
$38.13M
Kyverna Therapeutics, Inc.
Feb 14, 2024
Ten Percent Owner
Uninformative Buy
$88.81M
List of latest transactions for each holding click on a transaction to see Bain Capital Life Sciences Investors, LLC's performance on stock

Bain Capital Life Sciences Investors, LLC insider profile FAQ

What is the percentage of profitable transactions made by Bain Capital Life Sciences Investors, LLC?
The percentage of profitable transactions made by Bain Capital Life Sciences Investors, LLC is 63%.
    What is the average return per transaction made by Bain Capital Life Sciences Investors, LLC?
    The average return per transaction made by Bain Capital Life Sciences Investors, LLC is 12.80%.
      What stocks does Bain Capital Life Sciences Investors, LLC hold?
      Bain Capital Life Sciences Investors, LLC holds: DRNA, MRNS, REPL, SWTX, ARQT, ANNX, APTX, RPID, XLO, SLDB, KYTX stocks.
        What was Bain Capital Life Sciences Investors, LLC’s latest transaction?
        Bain Capital Life Sciences Investors, LLC latest transaction was an Uninformative Buy of ―.
          What was Bain Capital Life Sciences Investors, LLC's most profitable transaction?
          Bain Capital Life Sciences Investors, LLC’s most profitable transaction was an Informative Buy of SWTX stock on September 19, 2019. The return on the trade was 96.70%.
            What is Bain Capital Life Sciences Investors, LLC's role in Dicerna Pharma?
            Bain Capital Life Sciences Investors, LLC's role in Dicerna Pharma is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.